Affimed NV (NASDAQ:AFMD) – Equities researchers at Jefferies Financial Group increased their FY2020 earnings estimates for Affimed in a research report issued to clients and investors on Monday, November 5th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings of $0.55 per share for the year, up from their prior forecast of ($0.75). Jefferies Financial Group currently has a “Buy” rating and a $4.00 target price on the stock. Jefferies Financial Group also issued estimates for Affimed’s FY2021 earnings at ($0.62) EPS and FY2022 earnings at $1.03 EPS.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Affimed from a “buy” rating to a “hold” rating in a research report on Friday. BMO Capital Markets dropped their target price on shares of Affimed from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, August 9th. ValuEngine lowered shares of Affimed from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. BidaskClub lowered shares of Affimed from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 18th. Finally, SunTrust Banks dropped their target price on shares of Affimed to $5.00 and set a “buy” rating for the company in a research report on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $4.81.
Affimed (NASDAQ:AFMD) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.05). Affimed had a negative return on equity of 77.87% and a negative net margin of 2,124.72%. The company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.30 million.
A number of institutional investors have recently added to or reduced their stakes in AFMD. CIBC World Markets Inc. purchased a new stake in shares of Affimed in the third quarter valued at $104,000. Renaissance Technologies LLC raised its stake in shares of Affimed by 38.8% in the second quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 49,610 shares during the period. Barclays PLC raised its stake in shares of Affimed by 385.3% in the first quarter. Barclays PLC now owns 64,958 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 51,573 shares during the period. Stanley Laman Group Ltd. purchased a new stake in shares of Affimed in the second quarter valued at $100,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Affimed by 28.8% in the first quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after acquiring an additional 71,545 shares during the period. 40.62% of the stock is currently owned by institutional investors.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Story: What is dollar cost averaging (DCA)?
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.